Market revenue in 2023 | USD 149.1 million |
Market revenue in 2030 | USD 895.9 million |
Growth rate | 29.2% (CAGR from 2023 to 2030) |
Largest segment | Pre-clinical |
Fastest growing segment | Pre-clinical |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-clinical, Clinical |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.13% in 2023. Horizon Databook has segmented the South Korea cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
South Korea is positioned as the world’s 10th-largest pharmaceutical market, which is identified as a significant driver for the country’s prospective economic expansion. The government has actively promoted local manufacturing of medicines, increasing the number of domestic pharmaceutical companies in the market in South Korea.
This growing government support is anticipated to propel the growth of the domestic pharmaceutical industry. Furthermore, key pharmaceutical companies are collaborating with local players to expand their market presence & strengthen their contract manufacturing capabilities in South Korea.
For instance, in October 2022, Medipost launched its CDMO business for cell & gene therapy products in Korea, featuring 10 cleanrooms and modern facilities.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into South Korea cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account